Lixte Biotechnology Holdings, Inc. - Common Stock (LIXT)
2.2800
-0.1800 (-7.32%)
Lixte Biotech Holdings is a biotechnology company focused on the discovery and development of novel therapeutics for the treatment of cancer and other life-threatening diseases
The company specializes in cell death pathways, aiming to identify and advance drug candidates that can effectively target and disrupt these pathways to induce cancer cell death. By leveraging its proprietary technology and research, Lixte seeks to bring innovative solutions to the market, contributing to the advancement of cancer treatment and improving patient outcomes.
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · November 5, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · October 29, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · October 29, 2024
![](https://cdn.benzinga.com/files/images/story/2024/10/29/VFCorp-Shutterstock.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · October 29, 2024
![](https://cdn.benzinga.com/files/images/story/2024/08/28/Tysons--Usa---January-26--2018-Nordstrom.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · August 28, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
Lixte Biotech Hldgs just reported results for the second quarter of 2024.
Via InvestorPlace · August 16, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · May 17, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
Lixte Biotech Hldgs just reported results for the first quarter of 2024.
Via InvestorPlace · May 9, 2024
![](https://cdn.benzinga.com/files/images/story/2024/03/27/image17.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded mostly higher toward the end of trading, with the Dow Jones index gaining over 300 points on Wednesday. The Dow traded up 0.78% to 39,589.55 while the NASDAQ fell 0.02% to 16,312.74. The S&P 500 also rose, gaining, 0.36% to 5,222.18.
Via Benzinga · March 27, 2024
![](https://cdn.benzinga.com/files/images/story/2024/03/27/image30_0.jpeg?width=1200&height=800&fit=crop)
Shares of LuxUrban Hotels Inc. (NASDAQLUXH) fell sharply during Wednesday’s session after the company issued preliminary fourth-quarter revenue outlook below estimates.
Via Benzinga · March 27, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · March 27, 2024
![](https://cdn.benzinga.com/files/images/story/2024/03/27/image41.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded mostly higher midway through trading, with the Dow Jones gaining over 200 points on Wednesday. The Dow traded up 0.56% to 39,502.25 while the NASDAQ fell 0.08% to 16,302.03. The S&P 500 also rose, gaining, 0.27% to 5,217.52.
Via Benzinga · March 27, 2024
![](https://cdn.benzinga.com/files/images/story/2024/ai-generated-pharmaceutical.jpeg?width=1200&height=800&fit=crop)
The company announced the publication of pre-clinical data in the online journal, "Cancer Discovery", showing that its lead clinical compound, LB-100, can force cancer cells to give up their cancer-causing properties in a paper entitled "Paradoxical activation of oncogenic signaling as a cancer treatment strategy."
Via Benzinga · March 27, 2024
![](https://cdn.benzinga.com/files/images/story/2024/03/27/image48.jpg?width=1200&height=800&fit=crop)
U.S. stocks traded higher this morning, with the Dow Jones gaining over 200 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.58% to 39,511.62 while the NASDAQ rose 0.60% to 16,412.89. The S&P 500 also rose, gaining, 0.58% to 5,233.65.
Via Benzinga · March 27, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · March 27, 2024
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
Lixte Biotech Hldgs just reported results for the fourth quarter of 2023.
Via InvestorPlace · March 19, 2024
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · October 26, 2023
![](https://cdn.benzinga.com/files/images/story/2023/10/06/image19.jpg?width=1200&height=800&fit=crop)
The Dow Jones closed lower by around 10 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · October 6, 2023
![](https://cdn.benzinga.com/files/images/story/2023/10/05/image27.jpeg?width=1200&height=800&fit=crop)
The Dow Jones closed higher by over 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Via Benzinga · October 5, 2023
![](https://investorplace.com/wp-content/uploads/2021/05/wall-street-morning.jpg)
Pre-market stock movers are worth checking out on Monday as we start off the week with all the latest news this morning!
Via InvestorPlace · October 2, 2023
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
Friday's session saw 59 companies set new 52-week lows.
Via Benzinga · July 28, 2023
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Via Benzinga · July 27, 2023
![](https://cdn.benzinga.com/files/images/story/2023/07/27/celestica_-_logo.jpg?width=1200&height=800&fit=crop)
Gainers Celestica Inc. (NYSECLS) shares surged 42.2% to $23.40 in pre-market trading after the company announced better-than-expected second-quarter results.
Via Benzinga · July 27, 2023
![](https://cdn.benzinga.com/files/images/story/2023/07/27/willis_towers_watson_-_logo.jpg?width=1200&height=800&fit=crop)
Gainers Femasys Inc. (NASDAQFEMY) gained 54% to $0.55. Femasys reported a notice of allowance for new U.S. patent application covering use of FemBloc for female permanent birth control.
Via Benzinga · July 27, 2023